Siamak Moghadam-Kia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11681526/publications.pdf

Version: 2024-02-01

17	993	623188	887659
papers	citations	14 h-index	17 g-index

17	17	17	1453
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention and treatment of systemic glucocorticoid side effects. International Journal of Dermatology, 2010, 49, 239-248.	0.5	218
2	Antiâ€“Melanoma Differentiationâ€“Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care and Research, 2016, 68, 689-694.	1.5	199
3	Approach to asymptomatic creatine kinase elevation. Cleveland Clinic Journal of Medicine, 2016, 83, 37-42.	0.6	117
4	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. Journal of Rheumatology, 2017, 44, 319-325.	1.0	112
5	Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology, 2019, 58, 1011-1015.	0.9	68
6	Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosusâ€“Associated Skin Lesions. Archives of Dermatology, 2009, 145, 255-60.	1.7	54
7	Autoimmune Disease and Hair Loss. Dermatologic Clinics, 2013, 31, 75-91.	1.0	40
8	Anti-MDA5 Antibody Spectrum in Western World. Current Rheumatology Reports, 2018, 20, 78.	2.1	40
9	Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Review of Clinical Immunology, 2015, 11, 1265-1275.	1.3	27
10	A diagnostic and therapeutic approach to primary burning mouth syndrome. Clinics in Dermatology, 2017, 35, 453-460.	0.8	25
11	Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clinical Reviews in Allergy and Immunology, 2017, 52, 81-87.	2.9	21
12	Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. Rheumatology, 2021, 60, 5713-5723.	0.9	17
13	Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. Seminars in Arthritis and Rheumatism, 2021, 51, 539-546.	1.6	17
14	Imaging with (18)F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring. Hellenic Journal of Nuclear Medicine, 2009, 12, 165-7.	0.2	15
15	Consumer-based activity trackers in evaluation of physical activity in myositis patients. Rheumatology, 2022, 61, 2951-2958.	0.9	11
16	Biologics for idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2017, 29, 645-651.	2.0	9
17	Myositis in clinical practiceâ€”relevance of new antibodies. Best Practice and Research in Clinical Rheumatology, 2018, 32, 887-901.	1.4	3